Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

BRCA Pioneer Offit Shares Insights on Evolving Testing Landscape

January 7th 2015

For more than two decades, Kenneth Offit, MD, MPH, has been researching the molecular genetic factors that increase cancer risk, notably concerning germline BRCA mutations in breast and ovarian cancer, with a focus on potential preventive surgical remedies and screening programs for women at hereditary risk.

Dr. Kaklamani on Triple Combination Treatment for Breast and Ovarian Cancer

December 31st 2014

Virginia Kaklamani, MD, a professor of medicine in the Division of Hematology/Oncology at the University of Texas Health Sciences Center at San Antonio, discusses a recent clinical trial that looks at the combination of two chemotherapy drugs, carboplatin and eribulin, along with the PARP inhibitor E7449 for the treatment of breast and ovarian cancer.

FDA Approves Olaparib for Advanced Ovarian Cancer

December 19th 2014

The FDA has approved the PARP inhibitor olaparib (Lynparza) for the treatment of women with BRCA-positive advanced ovarian cancer.

The New BRCA1/2 Landscape

December 13th 2014

As one of the most significant predictors of hereditary breast and ovarian cancer, the BRCA1/2 genes have become the poster child for genetic testing, thrust into the limelight by a high-profile court battle and a celebrity's disclosure.

Latest News & Insight: November 26, 2014

November 27th 2014

PARP Inhibitors for Breast and Ovarian Cancers

November 26th 2014

PARP inhibitors represent an exciting new class of anticancer agents and are currently being evaluating in phase III for a number of different indications.

Challenges for the Future of Gynecologic Cancers

November 26th 2014

Emerging Therapies in Cervical Cancer

November 26th 2014

Bevacizumab in Recurrent Metastatic Cervical Cancer

November 26th 2014

Cervical Cancer Screening and Prevention

November 26th 2014

Promising Treatments in Ovarian Cancer

November 26th 2014

Bevacizumab in Ovarian Cancer

November 26th 2014

Platinum Resistance in Ovarian Cancer

November 26th 2014

CA-125 Testing in Ovarian Cancer

November 26th 2014

Intraperitoneal Chemotherapy in Ovarian Cancer

November 26th 2014

Antiangiogenic Agents in Ovarian Cancer

November 26th 2014

Treatment Options in Ovarian Cancer

November 26th 2014

Chemotherapy Regimens for Ovarian Cancer

November 26th 2014

Goal of Surgery in Ovarian Cancer

November 26th 2014

Cytoreductive Surgery for Ovarian Cancer

November 26th 2014